	<u> </u>	<u>ا</u> -
Please type a plus sign (+) inside this	+	

02-01-02


PTO/SB/05 (3-01) Proved for use through 09/30/2000. OMB 0651-0032 ark Office: U.S. DEPARTMENT OF COMMERCE

## UTILITY

Attomey Docket No.	PC11013A
First Inventor	John P. Mueller
Title	HarA Polypeptides and Nucleic Acids, and Related Methods and Uses Thereof
Francisco Maillet et et Me	E1 005574004U0

3	PATENT APPLICATION	First inventor	John P. Mueller						
E ·	TRANSMITTAL	Title		HarA Polypepti Methods and U		ides and Nucleic Acids, and Related Jses Thereof		d	
(Onl	y for new nonapplications under 37C.F.R. §1.53(b))	Express Mail La	abel No.	EL625	571291L	JS			
See	• APPLICATION ELEMENTS  MPEP chapter 600 concerning utility patent application	contents.	ADI	DRESS 1	го:	Box Pate	sioner for Pater nt Application ton, DC 20231	nts O	
1. 2.	*Fee Transmittal Form (e.g., PTO/SB/17 (Submit an original, and a duplicate for fee procession of the	•	7		uter Prog ind/or Ar	gram (Appen nino Acid Se	cate, large tab idix) equence Subm	Signification of the state of t	/30/02
3.	See 37 CFR 1.27  Specification [Total Pages]	51	(ii d	<i>а.</i> 🔯		• •	le Copy (CRF	) 1100 100	
	<ul> <li>(preferred arrangement set forth below)</li> <li>Descriptive title of the Invention</li> <li>Cross References to Related Applica</li> <li>Statement Regarding Fed sponsored</li> <li>Reference to sequence listing, a table or a computer program listing appear</li> </ul>	R&D e,		i. [ ii. [2 c. [X]	CD-R Paper Staten	nent verifying	(2 copies)		-
	<ul> <li>Background of the Invention</li> <li>Brief Summary of the Invention</li> </ul>			ACCO	MPAN	ING APPL	LICATION P	ARIS	
	Brief Description of the Drawings (if fit Description     Detailed Description     Claim(s)     Abstract of the Disclosure	iled)	9	37 CFI	R 3.73(b)	apers (cover Statement an assignee		iment(s)) ower of Atto	rney
	•		11.	Englis	h Transl	ation Docum	nent (if applica	ible)	
4.	Drawing(s) (35 U.S.C. 113) [Total sheets	8 l	12.	4		sciosure S)/PTO-1449		opies of IDS itations	
5.	Oath or Declaration [Total pages	1	13.	Prelim	ninary Ar	nendment			
	a. Newly executed (original or copy b. Copy from a prior application (37 CFF	R §1.63(d))	14.	- (Shou	ld be sp	t Postcard (lecifically iter	nized)		
	(for continuation/divisional with Box 1		15.	_		of Priority D			
	i. DELETION OF INVEN Signed statement attached deleting named in the prior application, see 1.63(d)(2) and 1.33(b).	inventor(s)	(if foreign priority is claimed)  16. Nonpublication Request under 35 U.S.C. 122 (b)(2)(B)(i). Applicant must attach form PTO/SB/35 or its equivalent.						
6	Application Data Sheet. See 37 CFR 1.7	76	17.	Other	-				
18.	If a CONTINUING APPLICATION, check approor in an Application Data Sheet under 37CFR 1.76.	opriate box, and su	oply the requ	isite inform	nation bei	low and in a pi	reliminary amen	dment,	
	Continuation Divisional	Continuation	-in-part (CII	P)	of pri	or applicatio	n No:/_		
	Prior application information: Examine					Group/Art			
Box	CONTINUATION OR DIVISIONAL APPS only. The en 5b is considered a part of the disclosure of the acc incorporation can only be relied upon when a portion of the control of	ompanying contin on has been inadv	uation or di ertentiy omi	visional a	pplication the subr	n and is here	by incorporate	supplied und d by reference	der ce.
_	18.	CORRESP							
$\succeq$	Customer Number or Bar Code Label	tomer No. or Attac	n bar code i	abel here	or or	Correspo	ndence address	; below	
Nar	ne ·						•		
	dress						1		
City		State		•		Zip Code			
Col		lephone	Pogletne"	- M- 11	140	Fax	44.242		_
	NAME (Print/type) Jeffrey N. Myers Signature	m	Registratio	<u>) NO. (</u> /	Attorney/. Date	Agent)	41,213	2002	$\dashv$
	Signature \\/\mathcal{I}/\math				Date		January 30,	2002	

					Under	rwork reduction Act of 19	95, no persoi	ns are requir	ed to respon		mplete if Kn	on unles it displays a valid OMB o	ontrol number.	
FEE TRANSMITTAL					Application Number									
For FY 2001						Filing Date				January 30, 2002				
			•				First Named Inventor John P. Mueller							
	Pati	ent Fee	e ar	re suhi	ect to annual	Revision		er Name					_	
Total Am					(\$)1076.00	TOVISION	Group/A	V Docket N			DC44042A			
					PAYMENT		Attorney	Docket		ECAL	PC11013A			
1. 🛛					ereby authorized	I to chame	2 ADDI	TIONAL		ECAL	CULATION (	continuea)		
🖂					lit any over payn	•	Ja. ADDI	HONAL	FEES					
Deposit		16-14												
Account Number				· · · · · · · · · · · · · · · · · · ·			Fee Code	Large Entity	Fee Code	Small Entity	Fee Paid			
								Fee (\$)		Fee (\$)				
Deposit		Pfizer	Inc				105	130	205	65	Surcharge - la	te fee or oath		
Account Name														
$\boxtimes$	Char	ge Any Ad	dditio	nal Fee	Required		127	50	227	25	Surcharge-late	filing fee or		
_		r 37 CFR									cover sheet			
	Appli	icant claim	ns sn	nall entity	status.		139	130	139	130	Non-English sp	pecification		
<u>C</u>	See	37 CFR 1.	.27				147	2,520	147	2,520	For filing a requ	uest for ex parte rexamination		
<u>a</u>	Payr	nent Encl	losed	d:			112	920*	112	920°		blication of SIR prior to		
Check		Credit	t card	a 🗆	Money Order	Other	113	1,840*	113	1,840°	Examiner actio	n blication of SIR after		
		_		_							Examiner actio			
U				CALC	CULATION		115	110	215	55	Extension for re	enly within first month		
BASIC		ING FE	E				116	400	216	200	Extension for re	eply within second month		
Earge Entit		Small E	•				117	920	217	460	Extension for re	eply within third month		
Code (	66 (\$)	Fee Code	Fee (\$)	F	ee Description	Fee Paid	118	1,440	218	720	Extension for re	eply within fourth month		
701	740	201	355	5 Utilit	y filing fee	740	128	1,960	228	980	Extension for re	eply within fifth month		
106	330	206	165	Desi	gn filing fee		119	320	219	160	Notice of Appe	al		
=107	510	207	255	Plan	t filing fee		120	320	220	160	Filing a brief in	support of an appeal		
₩ 108 T	740	208	370		sue filing fee		121	280	221	140	Request for ora	Request for oral hearing		
L 4	160	214	80		g fee		138	1,510	138	1,510	Petition to institute a public use proceeding			
				OTAL (1)	<u>  (\$)</u>	740	140	110 1,280	240 241	55 640		ve - unavoidable		
2. EXTR	A CL	AIM FE	EES	•	Fee fro	·m	142	1,280	242	640		ve - unintentional		
		47		Extra Cl	alms belov						Utility issue fee	(or reissue)		
Total Claim	S	•	-20**		0 X	=	143	460	243	230	Design issue fe	e		
Independer Claims	nt	7.	- 3**=	=	4 X 84	<b>= 336</b>	144	620	244	310	Plant issue fee			
Multiple De	pende	nt				=	122	130	122	130	Petitions to the	Commissioner		
Large En	•	Small I	Entit	ty			123	. 50	123	50		under 37 CFR 1.17(q)		
Fee Fee Code		Fee F code	<b>-</b> ee	Fee	Description		126	180	126	180	_	Information Disclosure Stmt		
103	18	203		9 Cla	ims in excess of	20	581	40	581	40		h patent assignment per number of properties)		
102	84	202	4	12 Inde	ependent claims	in excess of 3	146	740	246	370		sion after final rejection		
104	280	204	14	o Mul	tiple dependent	claim, if not paid	149	740	249	370	For each additi	onal invention to be		
109	80	209	4	12 ••R	eissue independ		179	710	279	355		ined (37 CFR § 1.129(b)) est for Continued Examination(RCE)		
110	18	210		9 ••R	eissue claims in	ginal patent excess of 20 er original patent	169	900	169	900	Request for ex design applicat	pedited examination of a		
		SUBTO	TAL	(2)	(\$)	336.00	Other (spe	ecify)						
** or number previously paid, if greater, For Relssues, see above						*Reduced	by Basic Fi	ling Fee Pa	ld		Subtotal (3)	0		
SUBMITT	ED B	Y				•				Con	nplete (if applic	cable)		
Type or Printed Name					41,213	,		Teleph	one 212-733-5061					
Signature		- ;			111	1001								



## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF: Mueller, et al.

APPLICATION NO.:

Not Yet Known

: Examiner:

FILING DATE:

January 30, 2002

: Group Art Unit:

TITLE:

HAR A POLYPEPTIDES AND NUCLEIC :

ACIDS, AND RELATED METHODS AND

**USES THEREOF** 

Assistant Commissioner for Patents Washington, D.C. 20231

Sir:

## Statement under 37 C.F.R. 1.825

Pursuant to 37 C.F.R. 1.825 (b), attorney for applicants states that the copy of the Sequence Listing in Computer Readable Form is the same as the substitute paper copy of the Sequence Listing submitted herewith. Pursuant to 37 C.F.R. 1.825 (d), attorney for applicants states further, that the substitute Sequence Listing data is identical to that originally filed.

Date: <u>January</u> 30, 2002

Jeffrey N. Myers

Attorney for Applicant(s)

Reg. No. 41,213

Pfizer Inc Patent Department, 5th Floor 150 East 42nd Street New York, NY 10017-5612 (212) 733-5061



PFIZER DOCKET NUMBER: PC11013A

APPLICATION NUMBER: Unassigned

TITLE: HarA Polypeptides and Nucleic Acids, and Related Methods and Uses

Thereof

APPLICANTS: John P. Mueller, et al.

Express Mail mailing label number <u>EL625571291US</u>

Date of Deposit: January 30, 2002

I hereby certify that this correspondence is being deposited with the United States Postal Service as "Express Mail Post Office to Addressee" service under 37 C.F.R.1.10 on the date indicated above and is addressed to Commissioner for Patents, Box Patent Application, Washington, DC 20231.

By:	· .	Velma Vyain	
		(Signature of person mailing)	
	٠.	Vilma Pizarro	
		(Typed or printed name of person)	

Pfizer Inc.
Patent Department, 5th Floor
150 East 42nd Street
New York, NY 10017-5612